Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Acute Leukemias of Ambiguous Lineage Have Durable Response to Hypomethylating Agents Plus Venetoclax in Older Patients

Joshua A Fein, Sanjay Patel, Neela Easwar, Michal Bar-Natan, Amy Chadburn, Pinkal Desai, Julia Geyer, Michael Kluk, Madhu M Ouseph, Ellen K. Ritchie, Michael Samuel, Paul Simonson, Gail J. Roboz, Justin D. Kaner

Blood (2023) 142 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2023-190532

Published: 2023

Journal Articles

Molecular and Cytogenetic Characteristics of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Patients Exposed to Chemotherapy (CT) and/or Radiation (XRT)

Pinkal Desai, Yasmin Abaza, Hetty E. Carraway, Jason Chua, Michael Samuel, Cynthia Crispino, Bridget Foley, Sindhusha Veeraballi, Peter Doukas, Oluwatobi Odetola, Justin D. Kaner, Michal Bar-Natan, Ellen K. Ritchie, Gail J. Roboz

Blood (2023) 142 (Supplement 1): 821.

https://doi.org/10.1182/blood-2023-190478

Published: 2023

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia

Pinkal Desai, Mayumi Sugita, Rachel Heise, Madison Thies, Nuria Mencia Trinchant, Cynthia Crispino, Sharmaine Griffith-Baker, Rejxhis Prifti, Ashwini Kumar, Michael Samuel, Justin D. Kaner, Ellen Ritchie, Wendy Cozen, Michael S. Simon, Gail J. Roboz, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 8602–8604.

https://doi.org/10.1182/blood-2022-166825

Published: 2022

Journal Articles

PTPN11 mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)

Dennis Lee, Tyler Augi, Kata Alilovic, Nuria Mencia Trinchant, Eti Sinha, Jorge Contreras, Michael Samuel, Pinkal Desai, Michael Kluk, Brianna N Smith, Gail J. Roboz, Ellen Ritchie, Michael R. Savona, Monica L. Guzman, Justin D. Kaner

Blood (2022) 140 (Supplement 1): 3208–3209.

https://doi.org/10.1182/blood-2022-167068

Published: 2022

Journal Articles

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Justin D. Kaner, MD, Nuria Mencia-Trinchant, PhD, Ariel Schaap, MD, Gail J. Roboz, MD, Sangmin Lee, MD, Pinkal Desai, MD MPH, Michael Samuel, MD, Spencer Krichevsky, BS, Idongessit Udoyen, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Ellen K. Ritchie, MD

Blood (2018) 132 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2018-99-110319

Published: 2018

Journal Articles

Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

Pinkal Desai, MD MPH, Alfadel Alshaibani, MD, Xian Wu, MPH, Sangmin Lee, MD, Jingmei Hsu, MD, Ellen K. Ritchie, MD, Michael Samuel, MD, Sebastian A. Mayer, MD, Adrienne A. Phillips, MD MPH, Usama Gergis, MD M.B.A, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2018-99-118366

Published: 2018

Journal Articles

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Sangmin Lee, MD, Jingmei Hsu, MD, Yassine Tahri, MD, Zhengming Chen, PhD MPH, MS, Tsiporah B. Shore, MD, Ellen K. Ritchie, MD, Usama Gergis, MD M.B.A, Pinkal Desai, MD MPH, Sebastian A. Mayer, MD, Michael Samuel, MD, Adrienne A. Phillips, MD MPH, Melissa M. Cushing, MD, Gail J. Roboz, MD, Koen Van Besien, MD PhD

Blood (2018) 132 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2018-99-119946

Published: 2018

Journal Articles

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Brian R. Curtis, PhDMT(ASCP), Yen-Michael S. Hsu, MD PhD, Nikolai A. Podoltsev, MD PhD, Jill Lacy, MD, Susanna A Curtis, MD, Robert Andrew Desimone, MD, Michael Samuel, MD, Kristin Zutavern, BS, Daniel Bougie, PhD, Richard H. Aster, MD

Blood (2017) 130 (Supplement 1): 3625.

https://doi.org/10.1182/blood.V130.Suppl_1.3625.3625

Published: 2017

Journal Articles

Factors Affecting Transfusion Utilization in Acute Myeloid Leukemia (AML) Patients Undergoing Initial Therapy

Sangmin Lee, MD, Priscilla Parra, Idongessit Udoyen, Kartikey Grover, Kathleen Kane, Pinkal Desai, MDMPH, Michael Samuel, MD, Ellen K Ritchie, MD, Gail J. Roboz, MD, Melissa M. Cushing, MD

Blood (2017) 130 (Supplement 1): 3870.

https://doi.org/10.1182/blood.V130.Suppl_1.3870.3870

Published: 2017

Journal Articles

Adoptive Immunotherapy with Cord Blood (CB) Grafts Targeting Shared Inherited Paternal Antigens (IPA) and/or Non-Inherited Maternal Antigens (NIMA) during Induction Treatment for High Risk Myeloid Malignancies: Safety and Preliminary Results

Usama Gergis, MD, Koen Van Besien, MD PhD, Emeline Masson Frenet, PhD, Tsiporah B. Shore, MD, Sebastian A. Mayer, MD, Adrienne A. Phillips, MD MPH, Jingmei Hsu, MD PhD, Gail J. Roboz, MD, Ellen K Ritchie, MD, Joseph Scandura, MDPhD, Sangmin Lee, MD, Pinkal Desai, MDMPH, Michael Samuel, MD, Jeffrey Ball, MD, Maria S. Albano, PhD, Rodica Ciubotariu, MD PhD, Ludy Dobrila, PhD, Cynthia Romeo, PhD, Andromachi Scaradavou, MD

Blood (2017) 130 (Supplement 1): 2627.

https://doi.org/10.1182/blood.V130.Suppl_1.2627.2627

Published: 2017

Journal Articles

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Ellen K Ritchie, MD, Spencer Krichevsky, BS, Gail J. Roboz, MD, Richard T Silver, MD, Andrew I Schafer, MD, Joseph Scandura, MDPhD, Pinkal Desai, MD MPH, Sangmin Lee, MD, Michael Samuel, MD

Blood (2017) 130 (Supplement 1): 2910.

https://doi.org/10.1182/blood.V130.Suppl_1.2910.2910

Published: 2017

Journal Articles

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

Sangmin Lee, MD, Pinkal Desai, MDMPH, Bianca Edirisinghe, Samantha Pianello, Jack W. Singer, MD, Michael Samuel, MD, Ellen K Ritchie, MD, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2966.

https://doi.org/10.1182/blood.V130.Suppl_1.2966.2966

Published: 2017

Journal Articles

PI3 Kinase p110 Delta Is Required for Leukemic Cell Survival and Self-Renewal in t(8;21) Acute Myeloid Leukemia

Leanne Ostrodka, MD, Michael Samuel, MD, Taneisha Sinclair, Redwan Bhuiyan, Kira Gritsman, MD PhD

Blood (2016) 128 (22): 1553.

https://doi.org/10.1182/blood.V128.22.1553.1553

Published: 2016

NARROW

Acute Leukemias of Ambiguous Lineage Have Durable Response to Hypomethylating Agents Plus Venetoclax in Older Patients

Molecular and Cytogenetic Characteristics of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Patients Exposed to Chemotherapy (CT) and/or Radiation (XRT)

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia

PTPN11 mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Factors Affecting Transfusion Utilization in Acute Myeloid Leukemia (AML) Patients Undergoing Initial Therapy

Adoptive Immunotherapy with Cord Blood (CB) Grafts Targeting Shared Inherited Paternal Antigens (IPA) and/or Non-Inherited Maternal Antigens (NIMA) during Induction Treatment for High Risk Myeloid Malignancies: Safety and Preliminary Results

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

PI3 Kinase p110 Delta Is Required for Leukemic Cell Survival and Self-Renewal in t(8;21) Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only